Carbacyclin

Carbacyclin

SCHEMBL6172952

CCCCC[C@H](O)C=C[C@@H]1[C@H]2CC(=CCCCC(=O)O)C[C@H]2C[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 1.00
PPARA Q07869 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
PPARG P37231 1/20 1.00
ALDH1A1 P00352 4/20 0.71
PTGIR P43119 7/20 0.64
PTGER2 P43116 4/20 0.64
PTGER1 P34995 3/20 0.64
PTGER3 P43115 3/20 0.64
PTGDR Q13258 2/20 0.64
PTGER4 P35408 4/20 0.57
TBXA2R P21731 3/20 0.57
PTGFR P43088 2/20 0.57
LMNA P02545 2/20 0.57
SLCO2A1 Q92959 1/20 0.57
TSHR P16473 3/20 0.57
HPGD P15428 2/20 0.57
MAPK1 P28482 2/20 0.57
NR1I2 O75469 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbacyclin SCHEMBL30905566 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL13539945 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL11090152 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL9643974 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL10732794 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL10439712 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL24340889 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL6082848 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL1479163 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG
Carbacyclin SCHEMBL28444482 1.00 PPARD (1.00) PPARDPPARAMEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348275-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-12-07 US claimed
US-9763911-B2 Prostacyclin compositions for regulation of fracture repair and bone formation MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2017-09-19 US claimed
US-20150164853-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2015-06-18 US claimed
US-20210059997-A1 PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS UNIVERSITY OF FUKUI (JP) 2021-03-04 US disclosed
EP-3733203-A1 PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS University of Fukui (JP) 2020-11-04 EP disclosed
US-20170348275-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-12-07 US disclosed
US-9763911-B2 Prostacyclin compositions for regulation of fracture repair and bone formation MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2017-09-19 US disclosed
US-20150164853-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2015-06-18 US disclosed
EP-1201235-B1 NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT TEIJIN LTD (JP) 2005-10-12 EP disclosed
EP-1201235-A1 NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT TEIJIN LIMITED (JP) 2002-05-02 EP disclosed
US-4692464-A Novel prostacyclin derivatives and a process for the preparation thereof SCHERING AKTIENGESELLSCHAFT (DE) 1987-09-08 US disclosed
US-4359581-A Process for the production of caracyclin intermediates SCHERING AG (DE) 1982-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164853-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION PTGIR, PTGIS, PTGS1 PPARD 847/4885PPARA 649/4885MEN1 4003/4885
US-20170348275-A1 PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION PTGIR, PTGIS, PTGS1 PPARD 847/4885PPARA 649/4885MEN1 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.